Backgrounds: Type I diabetes mellitus (T1DM), an autoimmune disease, is associated with insulin deficiency due to the death of -cells. Bone marrow-derived mesenchymal stem cells (BM-MSCs) are capable of tissue repair and thus are a promising source of -cell surrogates.
INTRODUCTION
Type 1 diabetes mellitus (T1DM), an autoimmune disease associated with certain genetic human leukocyte antigen configurations, results in the death of pancreatic -cells due to continued autoimmune activity, thereby leading to insulin deficiency (1) . During embryonic development, the pancreas originates from the foregut endoderm as ventral and dorsal buds (2) . Pancreatic progenitor cells within the foregut epithelium are marked by the expression of pancreatic-duodenal homeobox 1 (PDX-1), which can be activated by forkhead box A2 (FoxA2) and is required for pancreatic bud growth (3) . PDX-1 expression is down-regulated in acinar and ductal cells, maintained in differentiated endocrine cells, and up-regulated in -cells (4) . Also, Huang et al. (5) found that a pro-endocrine transcription factor, neurogenin 3 (Ngn3), induces expression of essential -cell transcription factors, such as paired box gene 4 (Pax4), during pancreatic development.
Adult stem cells are widely used in medical research due to their unique properties of self-renewal and ability to differentiate into multiple lineages (6) . Two popular types of stem cell populations are contained in bone marrow (BM):
hematopoietic stem cells and mesenchymal stem cells (MSCs).
MSCs are favored for cell-based therapies because of their multipotency and immune-modulatory properties, with several groups reporting the ability of MSCs to minimize the risk of graft-versus-host disease after allogeneic transplantation in patients (7) (8) (9) (10) (11) . MSCs can potentially be induced to differentiate into -cell-like, insulin-producing cells via exposure to specific differentiation factors or genetic modification (12) . Oh et al. (13) found that introducing MSCs into diabetic mice via subcapsular renal transplantation lowered blood glucose levels, demonstrating that BMderived cells are capable of differentiating into insulin-producing cells and suggesting their potential application for T1DM treatment.
The expansion of -cells from a progenitor/stem cell source is a practical solution to the shortage of donor islets, as several research groups have shown that multipotent MSCs are capable of giving rise to functional endoderm (13) (14) (15) (16) , and numerous studies show that stem cells of various origins can differentiate into islet-like cells (17, 18) . Furthermore, several studies have demonstrated that progenitor/stem cells, including BM-derived cells, can differentiate into insulinsecreting cells in vitro, and transplantation of these differentiated cells into diabetic mice reduces hyperglycemia (13, (19) (20) (21) .
All-trans retinoic acid (RA) is a signaling molecule involved in the development of neuroectoderm and mesoderm in vertebrates. RA also regulates early pancreatic bud formation during embryogenesis and enhances insulin expression in pancreatic -cells (22) , and RA signaling is involved in the emergence of Pdx1-expressing progenitor cells (23) . Cavallari et al.(24) demonstrated that RA, coupled with hyaluronic and butyric acids, can improve islet revascularization when islets are co-transplanted with stem cells into diabetic rats. Here, we examined the potential of RA to induce differentiation of rat BM-derived MSCs into the -cell lineage in vitro without using growth factors.
Furthermore, we investigated the potential in vivo therapeutic use of differentiated, insulin-secreting MSCs for T1DM.
MATERIALS AND METHODS

Cell isolation and expansion
Rat BM-derived MSCs (rBM-MSCs) were isolated from male 10-week-old Sprague Dawley (SD) rats (Orient, Seongnam, Korea). After sacrifice, the femora and tibiae were removed. Both ends of the bones were cut off, and BM aspirate was obtained by irrigation of phosphate buffered saline (PBS) through the bone using a syringe.
Aspirate was suspended in PBS, filtered through a cell strainer with 100-m pore size, and centrifuged at 800 ×g for 10 minutes and centrifuged at 800 ×g for 10 minutes. 
Enzyme-linked immunosorbent assay
Culture media from differentiated hBM-and rBM-MSCs ferentiated MSCs (n=8) were observed over an 8-weekperiod. Non-diabetic rats were observed as positive controls, and untreated STZ-induced rats were observed as negative controls. Glucose levels were checked every 3 days. Nephrectomy of the graft-bearing kidney was performed at the end of the observation period, and rats were monitored for an additional 6 days.
Immunohistochemistry
Removed graft-bearing kidneys were frozen in plastic 
Statistical analysis
Quantitative results are expressed as mean±standard deviation. Paired t-tests were used to compare groups using GraphPad Prism 6 for Windows (GraphPad Software, Inc., La Jolla, CA, USA). Statistical significance was set at P＜ 0.05.
RESULTS
Characterization of rBM-MSCs
rBM-derived cells were predominately positive for CD29
and CD90 (94.47% and 83.72%, respectively) ( Fig. 1) but negative for CD34 and CD45 (both 0.02%). Prior to induction of differentiation, cells were spindle-shaped with typical MSC-like morphology (Fig. 2) .
Morphology of differentiated rBM-MSCs
After RA treatment, morphological changes of rBMMSCs were monitored on a weekly basis. rBM-MSCs showed considerable alterations in their appearance across weeks (Fig. 2) . Cells typically exhibited polygonal or round shapes with radial nuclei. was clearly observed in differentiated cells (Fig. 4) .
ELISA revealed that differentiated rBM-MSCs showed a 2.063-fold increase in insulin secretion, which was significantly higher than that observed for MSCs cultivated in normal medium (P＜0.05; Fig. 5 ).
Syngeneic graft of rBM-MSCs in vivo
Non-diabetic (＋control) and STZ-injected rats (sham) exhibited obvious differences in blood glucose levels, with non-diabetic rats maintaining normoglycemia but diabetic rats exhibiting hyperglycemia (Fig. 6A) . Diabetic rats that received normal MSCs showed no reduction of hyperglycemia across the 3-week observation period, whereas diabetic rats that received differentiated MSCs showed a modest decrease in blood glucose level (Fig. 7B) . Linear regression analysis revealed that differentiated MSCs reduced blood glucose levels more rapidly than normal MSCs (slope for the differentiated MSC-injected group=−1.728±0.7725
vs. slope for the normal MSC-injected=−0.4935±0.5103) (Fig. 6D ).
When we continued to observe differentiated MSC-injected rats for an additional 5 weeks, we found that blood glucose levels remained below 400 mg/dL throughout the entire observation period (Fig. 6C) . Furthermore, rats exhibited a rise in blood glucose levels after nephrectomy of the grafted kidney.
Histological observation of grafted rBM-MSCs
rBM-MSCs were labeled with red fluorescent PKH26 prior to their injection. Three weeks after injection, we observed labeled cells mostly along the membrane near the injection site, with some cells partially migrating into the kidney (Fig. 8) . Insulin-and hematoxylin-stained images show that grafted cells successfully survived along the inner surface of the tissue membrane (Fig. 7) .
DISCUSSION
The generation of insulin-producing -cell surrogates from progenitor/stem cells in vitro has remarkable potential for a cell-based therapy for T1DM (13, (17) (18) (19) (20) (21) . However, the that MSCs from rats secreted insulin (Fig. 5 ) and express C-peptide (Fig. 3) . Nevertheless, we conclude that these cells cannot be considered as -cells but only as candidates with potential. Limitations clearly remain, which we are seriously taking into account to resolve in the next study.
T1DM is primarily an autoimmune disease, and, as a consequence, graft function progressively declines due to the loss of functional islets during the early post-transplantation period (35) . Therefore, the present study focused on MSCs, which could play a major role in tissue regeneration through localized immune-suppressive effects. To increase the functional activity of MSCs in vivo, we induced their differ- entiation by culturing MSCs in a customized differentiation medium for 3 weeks before their graft into the left kidney capsule of rats. Differentiated MSCs were modestly more effective than undifferentiated cells in reducing blood glucose levels (Fig. 6) , and differentiated MSCs successfully survived in the kidney for at least 3 weeks (Fig. 7, 8 ).
Furthermore, after nephrectomy of the grafted kidney, rats exhibited a return of high blood glucose levels. Although T1DM is an acute disease, we assume that grafted MSCs may enable chronic recovery, aiding in secretion of insulin.
Several research groups report that RA can regulate the commitment of embryonic stem cells to establish pancreatic endoderm (29, 30, 36) . However, detailed in vivo evidence of recovered function does not exist, and there has been no attempt to use MSCs, which entail fewer ethical concerns and are more clinically applicable. Thus, the results of the present study are compelling, as they clearly show a reduction in blood glucose levels and the survival of MSCs 3 weeks after injection. We conclude that RA-induced -cell differentiation of BM-MSCs may have great therapeutic potential for T1DM.
One may argue that the sustained reduction of blood glucose levels in the present study was still too high to be considered normoglycemia. However, we find this data to be meaningful because only a very low number of cells (1× 106 cells per rat) were injected into rats. Increasing the number of injected cells could be explored in future studies as a way to improve the effectiveness of this potential therapeutic tool. Furthermore, diabetic rats initially exhibited excessively high levels of blood glucose, (i.e., typically above 500 mg/dL), meaning that the observed reduction in blood glucose levels could be considered evidence that the differentiated cells aided in the recovery of insulin secretion. It is also noteworthy that blood glucose level appeared to be continuously regulated, without a single instance of a rapid return to hyperglycemia throughout both the short-and long-term observation periods.
CONCLUSION
In summary, we showed that RA can induce the differentiation of rBM-MSCs into the -cell lineage, resulting in cells that have the ability to secrete insulin. Furthermore, the success of grafted MSCs in a rat model of diabetes suggests that MSCs can potentially serve as -cell surrogates within therapies for T1DM.
